Genoptix Announces National Three-Year Agreement With Aetna

CARLSBAD, Calif., Feb. 25 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX) today announced that it will participate in Aetna's (AET) national provider network to offer specialized laboratory and comprehensive diagnostic services designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma.

As a result, physicians will have additional choices for in-network specialty lab services for Aetna members. Aetna members could also benefit from lower out-of-pocket costs for Genoptix's laboratory services since copays, deductibles and coinsurance will be based on their in-network benefit levels and established rates for Genoptix's laboratory services.  The three-year agreement with Aetna, one of the nation's largest health benefits companies serving 19 million medical members, is effective April 1, 2010. Additional terms of the contract were not disclosed.

"We are excited to announce our contract with Aetna, a significant milestone for Genoptix," said Tina S. Nova, Ph.D., President and CEO of Genoptix.  "This relationship gives us the opportunity to make our specialized diagnostic services more accessible to Aetna's participating physicians and their patients across the country. We are proud to extend the benefits afforded by our offerings and our commitment to maintaining the highest standards in diagnostics for our physician customers."  

About Genoptix, Inc.

Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix's highly trained group of hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports.  Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma. Founded in 1999, Genoptix is traded on the Nasdaq Select Global Market and is a member of the S&P SmallCap 600 Index.  Genoptix is headquartered in Carlsbad, California. For more information, please visit www.genoptix.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release regarding the business of the companies that are not historical facts may be considered "forward-looking statements," including statements regarding the agreement between Genoptix and Aetna and the anticipated benefits related thereto, and Genoptix's ability to expand its reach and provide high quality specialized laboratory and comprehensive diagnostic services in regions across the country.  Forward-looking statements are based on current expectations and are subject to risks and uncertainties, which may cause actual results to differ materially and adversely from those set forth in the forward-looking statements.  These risks and uncertainties with respect to Genoptix are detailed in its most recent Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q as well as in subsequent filings with the United States Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The companies undertake no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

SOURCE Genoptix, Inc.